



Primary Bile Acid Disorders: A Largely Unknown Group of Rare Genetic Diseases in Newborns

Stefan Bittmann ^{a,b,c++#*}

^a Department of Pediatrics, Ped Mind Institute (PMI), Germany.

^b Department of Pediatrics, Hindenburgring 4, D-48599 Gronau, Germany.

^c Shangluo Vocational and Technical College, Shangluo, 726000, Shaanxi, China.

Author's contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/AJPR/2024/v14i5340

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/114932>

Minireview Article

Received: 25/01/2024

Accepted: 31/03/2024

Published: 02/04/2024

ABSTRACT

Primary bile acid disorders (BASD) in newborns are rarely found with a prevalence of 1-9/1,000,000 and include 1-2 % of all cases with neonatal cholestasis. Causes are different gene defects, which lead to liver enzyme defects, which play a major role in both cholic acid pathways, the classical with production of cholic acid and the alternative one with chenodeoxycholic acid. They are found in both genders in the same distribution. Early diagnosis is very important to introduce a bile acid replacement therapy as soon as possible as the treatment of choice to date. Diagnosis will be confirmed by molecular testing, liver biopsy and different forms of mass spectrometry methods. Differential diagnosis includes progressive familial intrahepatic cholestasis, neonatal hepatitis and biliary atresia. Further gene therapy approaches must be developed, like CRISPR Cas9 technology, to repair the spontaneous point mutations on DNA of these patients to cure and not to treat them their whole life finally.

⁺⁺ Head of Department;

[#] Visiting Professor;

^{*}Corresponding author: Email: stefanbittmann@gmx.de;

Keywords: BASD; children; cholestasis; bile acid.

1. INTRODUCTION

Inherited defects in bile acid synthesis are rare genetic disorders that can manifest as neonatal cholestasis, neurological issues, or deficiencies in fat-soluble vitamins [1-67]. There are nine recognized defects in bile acid synthesis, including deficiencies in oxysterol 7 α -hydroxylase, Δ 4-3-oxosteroid-5 β -reductase, 3 β -hydroxy- Δ 5-C27-steroid dehydrogenase, cerebrotendinous xanthomatosis (sterol 27-hydroxylase deficiency), α -methylacyl-CoA racemase, and Zellweger syndrome (cerebrohepatorenal syndrome). These conditions are characterized by the inability to produce normal bile acids and an accumulation of abnormal bile acids and bile acid intermediates. Individuals with inherited defects in bile acid synthesis typically have normal or low serum bile acid levels, normal γ -glutamyl transpeptidase levels, and no itching. "Failure to diagnose these conditions can lead to liver failure or chronic liver disease. Early identification can lead to significant clinical improvement with oral bile acid therapy. Inborn errors of bile acid synthesis are rare genetic disorders that account for 1–2% of neonatal cholestasis cases, characterized by conjugated or direct hyperbilirubinemia in early infancy. Most patients with inborn errors of bile acid synthesis respond well to oral bile acid therapy. Cholic acid and chenodeoxycholic acid, the primary bile acids, are produced through a series of enzymatic modifications to cholesterol involving at least 14 enzymes, multiple subcellular compartments, and two complementary chemical pathways. The main route for bile acid synthesis is the classic 'neutral' pathway, which produces both cholic acid and chenodeoxycholic acid in equal amounts. The rate-limiting step in this pathway is the modification of the steroid nucleus, catalyzed by cholesterol 7 α -hydroxylase. The farnesoid X receptor (FXR) regulates CYP7A1 through bile acids. FXR is a ligand-activated transcription factor that acts on target genes as a monomer or heterodimer with RXR. Bile acids are natural ligands for FXR, with chenodeoxycholic acid being the most potent activator. FXR activation leads to upregulation of SHP, which inhibits LRH-1's ability to activate CYP7A1. An alternative 'acidic' pathway involves C27-hydroxylation of cholesterol followed by C7 α -hydroxylation. Side-chain modification occurs after steroid nucleus modification in mitochondria and peroxisomes. The final step is the conjugation of cholic acid

and chenodeoxycholic acid to taurine or glycine" [68]. Deficiencies in genes encoding enzymes involved in bile acid synthesis pathways can cause liver disease by reducing canalicular bile acid secretion and accumulating potentially hepatotoxic bile acid precursors. These disruptions typically present as cholestasis in infants, resembling other neonatal liver diseases like biliary atresia.

2. CLASSICAL AND ALTERNATIVE BILE ACID PATHWAYS

Bile acid synthesis involves two pathways: the classic 'neutral' pathway and the alternative 'acidic' pathway. In the classic pathway, cholesterol is converted to 7 α -hydroxycholesterol by cholesterol 7 α -hydroxylase, which is the rate-limiting step. Enzymes like HSD3B7, sterol 12 α -hydroxylase, AKR1D1, and 3 α -hydroxysteroid dehydrogenase then modify the steroid nucleus and side chain to produce cholic acid and chenodeoxycholic acid. "In the alternative pathway, cholesterol is converted to 3 β -hydroxy-5-cholestanoic acid by CYP27A1, followed by conversion to 3 β , 7 α -dihydroxy-5-cholestenoic acid by CYP7B" [68].

3. DISCUSSION

"The prevalence of bile acid synthesis (BAS) defects is estimated to be around 1-9 per 1,000,000, excluding cerebrotendinous xanthomatosis" [1-67]. "Inborn errors in BAS likely contribute to 1-2% of unexplained liver diseases in infants, children, and adolescents" [3,7,9,11,23]. "The age at diagnosis varies, with presentations in infancy, childhood, or adulthood. Infants and children may experience complications due to fat malabsorption and vitamin deficiencies, leading to conditions like rickets, bleeding diathesis, neuroaxonal dystrophy, and night blindness" [1,5,7,9,14,24]. "There are seven known inborn errors of BAS causing liver cholestasis, including 3-beta-hydroxy-C27-steroid oxidoreductase deficiency (BAS defect type 1), delta4-3-oxosteroid-5-beta reductase deficiency (BAS defect type 2), oxysterol 7 α -hydroxylase deficiency (BAS defect type 3), 2-methylacyl-CoA racemase deficiency (BAS defect type 4), trihydroxycholestanoic acid (THCA) CoA oxidase deficiency, bile acid CoA ligase deficiency, and defective amidation, along with cerebrotendinous xanthomatosis" [16,23,24,37,68]. "Cholesterol

Table 1. Genetic, biochemical and clinical features of bile acid synthesis defects in the newborn

Enzyme defect	Gene encoding the affected enzyme (reference)	Urine bile acid profile	serum bile acid profile	Clinical features
Oxysterol 7 α -hydroxylase deficiency	CYP7B ¹⁴	↑ Sulfate and glycosulfate conjugates of 3 β - δ 5-monohydroxy bile acids Absence of primary bile acids	Extremely high levels of bile acids, primarily 3 β - δ 5-monohydroxy bile acids	Neonatal hepatitis (single reported case; unrecognized cases could be due to prenatal or early-postnatal death)
Δ^4 -3-oxosteroid-5 β -reductase deficiency	AKR1D1(SRD5B1)	↑ 3-oxo- δ 4 bile acids ↑ Allo bile acids ↓ Primary bile acids	↑ 3-oxo- δ 4 bile acids ↑ Allo bile acids ↓ Primary bile acids	Neonatal hepatitis with rapid progression to liver failure Neonatal hemochromatosis
3 β -hydroxy- Δ^5 -C ₂₇ -steroid dehydrogenase deficiency	HSD3B7	↑ Dihydroxy & trihydroxy cholenoic acids ↓ Primary bile acids	↓ or absence of primary bile acids	Neonatal hepatitis Late-onset liver disease Malabsorption
Cerebrotendinous xanthomatosis (sterol 27-hydroxylase deficiency)	CYP27A1	↑ Plasma cholestanol: cholesterol ratio	↑ Bile alcohol glucuronides	Progressive neurologic dysfunction in 2 nd –3 rd decade of life Chronic diarrhea Bilateral juvenile cataracts Neonatal cholestasis
Alpha methylacyl-CoA racemase deficiency	AMACR gene on chromosome 5p13.2-q11.1 ⁷¹	↑ C27 trihydroxycholestanoic and pristanic acid ↓ Primary bile acids	↑ C27 trihydroxycholestanoic and pristanic acid ↓ Primary bile acids Normal long-chain fatty acids and phytanic acid	Adult onset peripheral neuropathy Neonatal cholestasis with considerable fat-soluble-vitamin deficiency
Zellweger syndrome (cerebrohepatorenal syndrome)	12 PEX gene mutations; PEX1 mutations are the most common.	Atypical monohydroxy, dihydroxy and trihydroxy C27 bile acids ↓ Primary bile acids	↑ Long-chain fatty acids ↑ Cholestanic and pipecolic acid ↑ C29 dicarboxylic acid ↓ Primary bile acids	Craniofacial abnormalities Neuronal migration defects Polycystic kidneys

7alpha-hydroxylase deficiency leads to hypercholesterolemia without liver cholestasis. Diagnosis is based on hepatic enzyme and bilirubin profiles, along with urine, serum, and bile analysis using liquid secondary ionization mass spectrometry (LSIMS) and gas chromatography-mass spectrometry (GC-MS) [1-67]. Differential diagnoses include neonatal cholestasis, unexplained vitamin deficiencies, liver diseases, and neurologic conditions. Early diagnosis is crucial for initiating therapy before significant morbidity occurs. BAS defects share key clinical features, including normal or low total serum bile acid concentrations, minimally elevated γ -glutamyl transpeptidase (GGTP) levels, and absence of pruritus. A high index of suspicion is necessary to prevent overlooking these rare disorders, as they can mimic other liver conditions [75,76]. Early recognition and treatment offer an excellent prognosis, as many BAS defects are treatable. Treatment involves primary bile acid therapy, with cholic acid, ursodeoxycholic acid (UDCA), and glycocholic acid being used based on the specific defect [23,33,41,42]. Prognosis varies depending on the type of defect, with untreated cases leading to progressive liver disease or serious complications [34,37,43,67]. Early treatment can lead to long-term survival and clinical improvement [23,55,61].

4. CONCLUSION

BAS defects represent a rare significant group of liver disorders with similar presentations to other liver diseases, emphasizing the need for a high level of suspicion for accurate diagnosis. Early detection and treatment are essential for favourable outcomes in these rare conditions.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Ichimiya H, et al. Treatment of chronic liver disease caused by 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid. *Arch Dis Child*. 1990;65:1121–1124.
2. Setchell KD, et al. Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7 α -hydroxylase gene causes severe neonatal liver disease. *J Clin Invest*. 1998;102:1690–1703.
3. Schwarz M, et al. Disruption of cholesterol 7alpha-hydroxylase gene in mice: II. bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. *J Biol Chem*. 1996;271:18024–18031.
4. Schwarz M, et al. Identification and characterization of a mouse oxysterol 7alpha-hydroxylase cDNA. *J Biol Chem*. 1997;272:23995–24001.
5. Axelson M, Sjoval J. Potential bile acid precursors in plasma—Possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. *J Steroid Biochem*. 1990;36:631–640.
6. Shoda J, et al. Formation of 7 alpha- and 7-beta-hydroxylated bile acid precursors from 27-hydroxycholesterol in human liver microsomes and mitochondria. *Hepatology*. 1993;17:395–403.
7. Ishibashi S, et al. Disruption of cholesterol 7alpha-hydroxylase gene in mice: I. postnatal lethality reversed by bile acid and vitamin supplementation. *J Biol Chem*. 1996;271:18017–18023.
8. Gonzales E, et al. SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect. *J Hepatol*. 2004; 40:716–718.
9. Lemonde HA, et al. Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. *Gut*. 2003; 52:1494–1499.
10. Setchell KD, et al. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis: A new inborn error of bile acid synthesis. *J Clin Invest*. 1988;82:2148–2157.
11. Heubi JE, et al. Inborn errors of bile acid metabolism. *Semin Liver Dis*. 2007; 27:282–294.
12. Siafakas CG, et al. Abnormal bile acid metabolism and neonatal hemochromatosis: A subset with poor prognosis. *J Pediatr Gastroenterol Nutr*. 1997;25:321–326.
13. Shneider BL, et al. Delta 4-3-oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and hemochromatosis. *J Pediatr*. 1994;124: 234–238.

14. Clayton PT, et al. Delta 4-3-oxosteroid 5 beta-reductase deficiency: Failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. *Gut*. 1996;38:623–628.
15. Levy P, et al. Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats. *Gastroenterology*. 1991;101:1673–1679.
16. Clayton PT, et al. 3-Oxo-delta 4 bile acids in liver disease. *Lancet*. 1988;1:1283–1284.
17. Sumazaki R, et al. Gene analysis in delta 4-3-oxosteroid 5 beta-reductase deficiency. *Lancet*. 1997;349:329.
18. Bove KE, et al. Bile acid synthetic defects and liver disease. *Pediatr Dev Pathol*. 2000;3:1–16.
19. Daugherty CC, et al. Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta 4-3-oxosteroid 5 beta-reductase deficiency) *Hepatology*. 1993;18:1096–1101.
20. Bazzoli F, et al. Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey. *Dig Dis Sci*. 1982;27:417–424.
21. Sarva RP, et al. Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and bile acid composition in the Rhesus Monkey. *Gastroenterology*. 1980;79:629–636.
22. Wikvall K. Purification and properties of a 3 beta-hydroxy-delta 5-C27-steroid oxidoreductase from rabbit liver microsomes. *J Biol Chem*. 1981;256:3376–3380.
23. Clayton PT, et al. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. *J Clin Invest*. 1987;79:1031–1038.
24. Stieger B, et al. Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters. *Eur J Biochem*. 1997;244:39–44.
25. Buchmann MS, et al. Lack of 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase/isomerase in fibroblasts from a child with urinary excretion of 3 beta-hydroxy-delta 5-bile acids: a new inborn error of metabolism. *J Clin Invest*. 1990;86:2034–2037.
26. Schwarz M, et al. The bile acid synthetic gene 3beta-hydroxy-delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. *J Clin Invest*. 2000;106:1175–1184.
27. Cheng JB, et al. Molecular genetics of 3beta-hydroxy-delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. *J Clin Endocrinol Metab*. 2003;88:1833–1841.
28. Jacquemin E, et al. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. *J Pediatr*. 1994;125:379–384.
29. Horslen SP, et al. 3Beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology. *J Inherit Metab Dis*. 1992;15:38–46.
30. Witzleben CL, et al. A new category of causes of intrahepatic cholestasis. *Pediatr Pathol*. 1992;12:269–274.
31. Yamato Y, et al. 3Beta-hydroxy-delta5-C27-steroid dehydrogenase deficiency: Diagnosis and treatment. *J Paediatr Child Health*. 2001;37:516519.
32. Moghadasian MH, et al. Cerebrotendinous xanthomatosis: A rare disease with diverse manifestations. *Arch Neurol*. 2002;59:527–529.
33. Gallus GN, et al. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. *Neurol Sci*. 2006;27:143–149.
34. Verrips A, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. *Brain*. 2000;123:908–919.
35. Setchell KDR, Street JM. Inborn errors of bile acid synthesis. *Semin Liver Dis*. 1987;7:85–99.
36. Clayton PT, et al. Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: A new inborn error of bile acid synthesis? *Pediatr Res*. 1995;37:424–431.
37. Cruysberg JR, et al. Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. *Am J Ophthalmol*. 1991;112:606–607.
38. Wevers RA, et al. Paediatric cerebrotendinous xanthomatosis. *J Inherit Metab Dis*. 1992;15:374–376.

39. Setchell KDR, et al. Disorders of bile acid synthesis and metabolism: A metabolic basis for liver disease. In: Suchy FJ, et al., editors. *Liver Disease in Children*. New York: Cambridge University Press; 2007. pp. 736–766.
40. Bove KE, et al. Bile acid synthetic defects and liver disease: A comprehensive review. *Pediatr Dev Pathol*. 2004;7:315–334.
41. Westin S, et al. FXR, a therapeutic target for bile acid and lipid disorders. *Mini Rev Med Chem*. 2005;5:719–727.
42. Edwards PA, et al. BAREing it all: The adoption of LXR and FXR and their roles in lipid homeostasis. *J Lipid Res*. 2002;43:2–12.
43. Otte K, et al. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. *Mol Cell Biol*. 2003;23:864–872.
44. Makishima M, et al. Identification of a nuclear receptor for bile acids. *Science*. 1999;284:1362–1365.
45. Parks DJ, et al. Bile acids: Natural ligands for an orphan nuclear receptor. *Science*. 1999;284:1365–1368.
46. Wang H, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell*. 1999;3:543–553.
47. Goodwin B, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. *Mol Cell*. 2000;6:517–526.
48. Kuipers F, et al. The farnesoid X receptor (FXR) as modulator of bile acid metabolism. *Rev Endocr Metab Disord*. 2004;5:319–326.
49. Vlahcevic ZR, et al. Regulation of bile acid biosynthesis. *Gastroenterol Clin North Am*. 1999;28:1–25.
50. Russell DW, et al. Bile acid biosynthesis. *Biochemistry*. 1992;31:4737–4749.
51. Ichimiya H, et al. Bile acids and bile alcohols in a child with hepatic 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency: Effects of chenodeoxycholic acid treatment. *J Lipid Res*. 1991;32:829–841.
52. Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. *Am J Physiol Gastrointest Liver Physiol*. 2020 Mar 1;318(3):G554-G573. DOI: 10.1152/ajpgi.00223.2019 Epub 2020 Jan 27. PMID: 31984784; PMID: PMC7099488.
53. Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. *Gut*. 2018 Oct;67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307 Epub 2017 Aug 3. PMID: 28774887.
54. Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. *Mol Cell Endocrinol*. 2022 May 15;548:111618. DOI: 10.1016/j.mce.2022.111618. Epub 2022 Mar 11. PMID: 35283218; PMID: PMC9038687.
55. Chen HL, Wu SH, Hsu SH, Liou BY, Chen HL, Chang MH. Jaundice revisited: Recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. *J Biomed Sci*. 2018 Oct 26;25(1):75. DOI: 10.1186/s12929-018-0475-8 PMID: 30367658; PMID: PMC6203212.
56. Feldman AG, Sokol RJ. Neonatal cholestasis: Updates on diagnostics, therapeutics, and prevention. *Neoreviews*. 2021 Dec 1;22(12):e819-e836. DOI: 10.1542/neo.22-12-e819 PMID: 34850148; PMID: PMC10103174.
57. Farooqui N, Elhence A, Shalimar. A current understanding of bile acids in chronic liver disease. *J Clin Exp Hepatol*. 2022 Jan-Feb;12(1):155-173. DOI: 10.1016/j.jceh.2021.08.017 Epub 2021 Aug 23. PMID: 35068796; PMID: PMC8766695.
58. Bove KE. Liver disease caused by disorders of bile acid synthesis. *Clin Liver Dis*. 2000 Nov;4(4):831-48. DOI: 10.1016/s1089-3261(05)70144-6 PMID: 11232360.
59. Amendola M, Squires JE. Pediatric Genetic Cholestatic Liver Disease Overview. 2022 Sep 15 [updated 2023 May 25]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 36108118.
60. Vasavan T, Ferraro E, Ibrahim E, Dixon P, Gorelik J, Williamson C. Heart and bile

- acids - Clinical consequences of altered bile acid metabolism. *Biochim Biophys Acta Mol Basis Dis.* 2018 Apr;1864 (4 Pt B):1345-1355
DOI: 10.1016/j.bbadis.2017.12.039
Epub 2018 Jan 6.
PMID: 29317337.
61. Potter CJ. Cholestasis in the premature infant. *Clin Perinatol.* 2020 Jun;47(2):341-354.
DOI: 10.1016/j.clp.2020.02.009
Epub 2020 Mar 4.
PMID: 32439115.
62. Heubi JE, Bove KE, Setchell KDR. Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and zellweger spectrum disorders. *J Pediatr Gastroenterol Nutr.* 2017 Sep;65(3):321-326.
DOI: 10.1097/MPG.0000000000001657
PMID: 28644367;
PMCID: PMC5559188.
63. Baumann U, Sturm E, Lacaille F, Gonzalès E, Arnell H, Fischler B, Jørgensen MH, Thompson RJ, Mattsson JP, Ekelund M, Lindström E, Gillberg PG, Torfgård K, Soni PN. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. *Clin Res Hepatol Gastroenterol.* 2021 Sep;45(5):101751.
DOI: 10.1016/j.clinre.2021.101751.
Epub 2021 Jun 26.
PMID: 34182185.
64. Kriegermeier A, Green R. Pediatric cholestatic liver disease: Review of bile acid metabolism and discussion of current and emerging therapies. *Front Med (Lausanne).* 2020 May 5;7:149.
DOI: 10.3389/fmed.2020.00149
PMID: 32432119;
PMCID: PMC7214672.
65. Bedoyan SM, Lovell OT, Horslen SP, Squires JE. Odevixibat: A promising new treatment for progressive familial intrahepatic cholestasis. *Expert Opin Pharmacother.* 2022 Nov; 23(16):1771-1779.
DOI: 10.1080/14656566.2022.2140040
Epub 2022 Oct 30.
PMID: 36278881;
PMCID: PMC10074157
66. Fagan EA. Intrahepatic cholestasis of pregnancy. *Clin Liver Dis.* 1999 Aug;3(3):603-32.
DOI: 10.1016/s1089-3261(05)70087-8
PMID: 11291241.
67. Heubi JE, Setchell KDR. Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis. *J Pediatr Gastroenterol Nutr.* 2020 Apr;70(4):423-429.
DOI: 10.1097/MPG.0000000000002618
PMID: 31899729.
68. Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of disease: Inborn errors of bile acid synthesis. *Nature Clinical Practice Gastroenterology & Hepatology.* 2008 Aug;5(8):456-68.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/114932>